Kornimate/medical-research-clean huggingface dataset:
the association between loneliness and substance use

Conditions: Opioid Use; Loneliness

Summary: the proposed study will determine if cognitive behavioral therapy will help improve loneliness in people who use opioids.

the proposed study will be the first to assess the cognitive, affective, and behavioral pathways by which loneliness impacts opioid use. individuals with an opioid use disorder (oud) reporting loneliness will be randomized to either a 6-session cognitive- behavioral therapy for loneliness (cbt-l) or a 6-session education control condition, both delivered via telehealth. telehealth delivery can be easily implemented and can increase reach and access to individuals not engaged in treatment. we will use an established brief cbt manual to address loneliness. we will assess loneliness, negative affect (i.e., depression and anxiety), and the quality and quantity of social interactions prior to, during, and after the intervention to evaluate the subsequent impact on opioid use trajectories. participant will complete questionnaires pre-treatment, post-treatment, and at 1- and 2-months posttreatment.

Eligibility criteria:
inclusion criteria: * must be ages 18+ * understand english * have internet access * screen positive for an active oud on the oud module of the structured clinical interview for dsm-5 (diagnostic \& statistical manual of mental disorder, 5th edition) research version (scid-5-rv) * screen positive for loneliness by scoring at least a t-score \> 60 on the nih toolbox loneliness scale exclusion criteria: * consistent with previously used telehealth-delivered assessments, we will exclude any participant with cognitive impairment as measured by the blessed orientation-memory-concentration test (bomc) * potential participants who are in the process of detoxifying as measured by the subjective opiate withdrawal scale will also be excluded
enhancing patient recall in urogynecologic surgery

Conditions: Prolapse; Incontinence

Summary: patient counseling is an essential part of any new treatment implementation. this process becomes even more important when it involves surgical counseling. this is when the patient and the surgeon discuss the possible surgical options and ideally establish a plan for the appropriate surgical intervention. unfortunately, multiple studies have shown that patients tend to have poor recall of the key elements discussed during the consultation (1-3). in the investigators' experience, the concern lies specifically in the level of recall that patients have regarding their planned surgical procedure, as most patients cannot correctly state the planned intervention despite extensive counseling and explanation. lack of knowledge about the type of surgery can have serious implications for the patient in the future. for example, knowing facts like the presence or absence of the cervix and whether future pap smears are needed or the presence of an implant, such as a mesh are necessary for the patient's well-being and proper medical care down the line, especially when the patient has multiple medical providers. in addition, previous research has demonstrated that low-quality counseling and the feeling of being "unprepared for surgery" directly correlate with patient dissatisfaction (4). this is especially relevant in the field of female pelvic reconstructive surgery, where the success of surgical interventions relies heavily upon subjective patient-reported outcomes (5). there have been many studies to augment the counseling process using supplemental materials. these have included use of multiple visual charts, anatomical models, and passive and interactive audiovisual aids (6). some improvement in the outcomes has been observed in various fields of medicine with the dissemination of supplemental patient resources (7-10). however, in urogynecology, the effectiveness of surgical counseling sessions has not been achieved despite the different additional methods for patient education (6, 11). reasons that urogynecologic supplemental materials have not seen the same level of success as those in other fields of medicine include the complexity of the surgeries and the language used in many of these educational aids (12). the investigators aim to address the problem of poor patient recall of their procedure by providing them with an easy-to-read patient card detailing the anticipated surgery at the time of their consult.


Eligibility criteria:
inclusion criteria: * english-speaking females, ages \>18 and \<90 years, present for surgical planning for reconstructive urogynecologic procedures exclusion criteria: * dementia, blindness, non-english speakers
genematch: a program of the alzheimer's prevention registry to match individuals to studies based on apolipoprotein e (apoe) genotype

Conditions: Alzheimer Disease

Summary: the purpose of the alzheimer's prevention registry genematch program is to identify a large group of people interested in participating in research studies or clinical trials based in part on their genetic background. this genetic information will be used to match interested individuals to studies, providing a recruitment resource to the alzheimer's scientific community. interested individuals should visit www.endalznow.org/genematch to join the genematch program.

the primary objectives of the alzheimer's prevention registry genematch program are to (1) identify and characterize a large cohort of people who are interested in, and may be eligible to participate in, current and future preclinical alzheimer's disease research studies and clinical trials based on their genetic background, and (2) provide information to these individuals about research studies for which they may be eligible, based in part on their genetic background. cognitively unimpaired individuals age 50 to 90, inclusive, are eligible to enroll in genematch. genematch will provide participants with a genetic sample kit (a cheek swab) to test for a specific gene called apolipoproteins e (apoe). genematch does not disclose the results of the apoe test to participants. genematch may use the apoe test results to match participants to research studies. participants are under no obligation to pursue these study opportunities.

Eligibility criteria:
inclusion criteria: * age 50-90, inclusive * provide basic demographic, medical history, and contact information * consent to apoe genotyping without receiving results * live in the united states exclusion criteria: * unable to comply with this project's protocol requirements * self-reported diagnosis of dementia or any other objective cognitive impairment syndrome
arrhythmic effects of hight dose caffeine

Conditions: Arrhythmia

Summary: heart failure patients represent a group of individuals at higher risk for cardiac arrhythmias. there is a perception that caffeine consumption may represent an increase in this risk. although the medical staff and health professionals suggest a reduction in the intake of this substance to patients considered at risk, there is no scientific proof for this recommendation. some animal studies suggest a possible association between arrhythmias and caffeine use with higher doses, but this finding did not appear in human studies. in particular, little is known about the association between caffeine consumption and arrhythmias in patients with heart failure, especially at higher doses of consumption. more specific and safe guidelines on caffeine consumption are needed.


Eligibility criteria:
inclusion criteria: * heart failure in nyha functional class i-iii * lv ejection fraction \<45% * age \> 18 y.o. * cardio-defibrillator implanted with normal functioning with at least 30 days. exclusion criteria: * impossibility of take caffeine * inability to perform an exercise test * initial use of amiodarone in the last 2 months * unstable ventricular arrhythmias, shock or atp in the last 60 days * hospitalization in the last two months due to decompensated heart failure
a study to assess the effects of certolizumab pegol on the reduction of anterior uveitis (au) flares in axial spondyloarthritis subjects with a documented history of au

Conditions: Axial Spondyloarthritis (axSpA); Anterior Uveitis (AU)

Summary: the purpose of the study is to demonstrate the effect of certolizumab pegol (czp) treatment on the reduction of anterior uveitis (au) flares in subjects with active axial spondyloarthritis (axspa) and a documented history of au.


Eligibility criteria:
inclusion criteria: * subjects must have a documented diagnosis of adult-onset axial spondyloarthritis (axspa) with at least 3 months' symptom duration and meet the assessment of spondyloarthritis international society (asas) criteria * subjects must have active disease at screening as defined by * bath ankylosing spondylitis disease activity index (basdai) score \>= 4 * spinal pain \>= 4 on a 0 to 10 numerical rating scale (nrs; from basdai item 2) * nonradiographic (nr)-axspa subjects must either have c-reactive protein (crp) \> upper limit of normal (uln) and /or current evidence of sacroiliitis on magnetic resonance imaging (mri) (no confirmation by central reading) as defined by asas criteria * ankylosing spondylitis (as) subjects must have evidence of sacroiliitis on x-ray meeting the modified new york (mny) classification criteria according to the investigator * subjects must have a documented history of anterior uveitis (au) diagnosed by an ophthalmologist and have at least 2 au flares in the past, of which at least 1 au flare was in the last 12 months prior to baseline exclusion criteria: * other inflammatory arthritis * secondary, noninflammatory condition that, in the investigator's opinion, is symptomatic enough to interfere with evaluation of the effect of study drug on the subject's primary diagnosis of axial spondyloarthritis (axspa) * any history of uveitis except for anterior uveitis (au) associated with axspa * any condition or complicating factor that may interfere with the au assessment * retisert® or iluvien® (glucocorticosteroid implant) within 3 years prior to the baseline visit or has had complications related to the device * subject has had retisert or iluvien (glucocorticosteroid implant) removed within 90 days prior to the baseline visit * intraocular or periocular corticosteroids within 90 days prior to the baseline visit * ozurdex® (dexamethasone implant) within 6 months prior to the baseline visit * cyclophosphamide within 30 days prior to the baseline visit * intravitreal methotrexate (mtx) within 90 days prior to the baseline visit * intravitreal anti-vascular endothelial growth factor (vegf) therapy

Keywords: axial spondyloarthritis axspa anterior uveitis certolizumab pegol cimzia
the normal standard of brainstem auditory evoked potential in adults using a new device

Conditions: Normal Hearing (76 Subjects); Subjects With Hearing Loss (15 Subjects)

Summary: there are no differences between the exams made with the new device,that evaluates the hearing, and the device gold standard, that is widely used in clinics and hospitals.


Eligibility criteria:
inclusion criteria: * hearing thresholds less than 25 db at all frequencies of pure tone audiometry, with differences between the ears, by frequency, or less than 10 db. * the group with bilateral sensorineural hearing loss was made up of adults with hearing thresholds changed from 25 to 60 db hl for the frequencies 2000-8000 hz for pure tone audiometry. exclusion criteria: -

Keywords: evoked potentials, adult, hearing loss
allogeneic human mesenchymal stem cells for alzheimer's disease

Conditions: Alzheimer Dementia

Summary: study objectives primary: to assess the safety and tolerability of ischemia-tolerant allogeneic human mesenchymal stem cells (hmscs) manufactured by stemedica versus placebo administered intravenously to subjects with mild to moderate dementia due to alzheimer's disease. secondary: to assess the preliminary efficacy of hmscs versus placebo in subjects with alzheimer's-related dementia, as evidenced by neurologic, functional, and psychiatric endpoints.

this is a phase iia multi-center, randomized, single-blind, placebo-controlled, crossover study in subjects with mild to moderate dementia due to alzheimer's disease. only the subject and their caregiver will be blinded to the study treatment. the study will consist of two cohorts of subjects (20 subjects per cohort), randomized in a 1:1 allocation to receive active study drug or placebo. cohort 1 will receive a single intravenous dose of hmscs of 1.5 million cells per kilogram body weight on their study day 1, and cohort 2 will receive equal volume of lactated ringer's solution on their study day 1. at the six-month time point for each subject after their first infusion, cohort 1 will receive a single intravenous dose of lactated ringer's solution and cohort 2 will receive a single intravenous dose of hmscs at 1.5 million cells per kilogram of the subject's body weight. approximately 40 subjects will be enrolled in this study. an independent data and safety monitoring board will conduct periodic safety reviews.

Eligibility criteria:
inclusion criteria: 1. males or females between 55-80 years of age. 2. diagnosed with mild to moderate dementia for at least 3 months prior to enrollment, based on the national institute of neurological and communicative 3. disorders and stroke and the alzheimer's disease and related disorders association (ninds-adrda) alzheimer's criteria. 4. mmse between 12-24 (inclusive) at time of enrollment. 5. amyloid-positive florbetapir pet scan. exclusion criteria: 1. prior treatment with stem cells. 2. history of intracranial, subdural, or subarachnoid hemorrhage. 3. subjects with baseline brain mri showing more than four (4) cerebral microhemorrhages (regardless of their anatomical location or diagnostic characterization as "possible" or "definite"), and/or one (1) or more areas of superficial siderosis, and/or evidence of a prior macrohemorrhage. mri must include fluid-attenuation inversion recovery (flair) and t2\*-weighted gradient-recalled-echo (gre) sequences. 4. history of cancer within the past 5 years, with the exception of localized basal or squamous cell carcinoma. 5. history of seizure disorder. 6. diagnosis of cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (cadasil). 7. history of cerebral neoplasm. 8. myocardial infarction within six months of enrollment.
patent foramen ovale and the risk of postoperative delirium following elective hip and knee arthroplasty surgeries

Conditions: Foramen Ovale, Patent; Delirium; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee

Summary: this study will involve patients who are planned to have hip or knee replacement surgeries. they will undergo a transthoracic echocardiogram study (an ultrasound of the heart) to look for a patent foramen ovale (pfo). a pfo is a hole in the heart that everyone is born with and in most cases eventually closes by adulthood. however, it does not always close in all people. the investigators will compare the participants as two groups - those with a pfo, and those without, and look for differences in delirium in their postoperative stay. this will help us look for an association between postoperative delirium and the presence of a pfo.


Eligibility criteria:
inclusion criteria: * planned to undergo an elective, primary hip replacement surgery or knee replacement surgery * fluent in english exclusion criteria: * planned to undergo a revision knee or hip replacement * history of cardiac surgery or prosthetic heart valves * history of other structural heart abnormalities, not involving the atrial septum * history of preexisting neurologic condition that affects the patient's day-to-day life, including a history of dementia, stroke, or previous neurosurgery causing ongoing problems * significant visual problems felt by investigators to impair confusion assessment method use * significant hearing problems felt by investigators to impair confusion assessment method use * history of psychiatric problems requiring treatment with major antidepressant drugs or antipsychotic drugs * history of a deep venous thrombosis or pulmonary embolism in the past year * history of known atrial fibrillation in the past 3 months * presence of a pacemaker or implantable cardioverter-defibrillator * history of transient ischemic attack or stroke within the past year
active cue-training in neglect

Conditions: Hemispatial Neglect

Summary: the presented study investigates standardized visual cueing in reading and visual spatial task as a treatment method for spatial neglect. in a randomized controlled design patients receive either cued reading and visual spatial tasks (intervention) or treatment which is unspecific to neglect (control). in the intervention condition, patients with left-sided neglect receive intense training, including reading and visual spatial task with standardized and adapted visual cueing by the therapist. improvements in reading and visual spatial tasks lead to a reduction of cues by the therapist. accordingly, the patient has to apply self-cueing over time in order to solve the task. for the control condition, all patients receive unspecific treatment without any standardized adapted cueing implemented by the therapist. to enhance the effectivity of cueing in reading and visual spatial tasks, the investigators additionally conduct parietal transcranial direct current stimulation (tdcs) in those patients without tdcs exclusion criteria (see exclusion criteria below). it is hypothesised that systematic and adaptive therapeutic cueing leads to a significant reduction of omissions of word and word parts in reading. update: no add-on tdcs was performed since it was not applicable for our severly impaired patients due to the strict exclusion criteria of tdcs.


Eligibility criteria:
inclusion criteria: * left sided neglect * capacity of at least 30 minutes * ability to read in german language * mobilization of 80% exclusion criteria: * previous known dementia * normal pressure hydrocephalus exclusion criteria for tdcs add-on (not exclusion of the intervention): * shunt * craniectomy * epilepsy * other metal implants

Keywords: hemispatial neglect cueing egocentric-allocentric early rehabilitation parietal tdcs
cognitive sensorimotor training with whole body vibration for cognitive impairment

Conditions: Cognitive Impairment

Summary: aging is associated with cognitive decline, ranging from normal to mild cognitive impairment or dementia. this leads to physical and cognitive impairment, which are risk factors for loss of autonomy therefore physical and cognitive training are important for cognitively impaired older adults. cognitive somatosensory exercise (cse) is a special comprehensive rehabilitation program for retraining sensory-induced motor control, and whole-body vibration (wbv), which enhances neuromuscular function, cognition, and balance. this study aims to investigate the effects of combined cognitive sensory-motor training with whole-body vibration on cognition and balance in older adults with mild to moderate cognitive impairment. a double-blinded randomized control trial will be conducted for ten months. the sample size was calculated through g-power and 50 participants will be recruited through the non-probability convenience sampling technique. those who meet the inclusion criteria will be randomized into two groups (25 in the experimental group and 25 in the control group) through the online randomizer tool. the experimental group will receive cognitive sensorimotor training along with whole-body vibration. the control group will receive the cognitive sensorimotor training and motor-cognitive dual-task training (mcdtt) simultaneously. participants of each group will receive 60 minutes of training 3 times per week for 12 weeks. outcome measures include the montreal cognitive assessment (moca), the stroop test will be used for the measurement of cognition and cognitive flexibility, the mini bestest for static and dynamic balance, and the short physical performance battery for functional mobility. assessment will be done at baseline, after the 6th week, 12th week, and at 16th week. data analysis will be performed by using spss 26 software. mixed anova and repeated-measures anova will be used for within-group analysis whereas between-group analysis will be performed by using one-way anova.


Eligibility criteria:
inclusion criteria: * participants fulfilling given criteria will be included in this study * both male and female participants will be included * the age limit for the participants will be 60 to 75 * participants with mild to moderate cognitive impairment having a montreal cognitive assessment (moca) score of 13-25 (out of 30) * participants with mild to moderate balance impairment having mini bestest cut-off score 13-28 exclusion criteria: * participants having given criteria will be excluded from this study * participants having major depressive and anxiety disorder * participants having significant visual and auditory impairment * participants having a prior history of neurological disease or brain injury, and psychiatric disorders * participants having cerebrovascular infarction * participants having a neurological condition (epilepsy, loss of consciousness leading to a fall (e.g. vertigo syndrome)

Keywords: sensory motor training, wbv, functional mobility,short performance battery
hypoalbuminemia in burn patients

Conditions: Second or Third Degree Burns

Summary: the purpose of this study is to determine whether 5% human albumin solution, given to correct hypoalbuminemia, could improve organ dysfunction in burn patients as assessed by a change in the sofa score from baseline to day 7 (or before if the patient is discharged from the icu or died).

each year approximately 2 million people are burned in the usa, from which 80,000 are hospitalized and 6,500 die. it is a well known fact that the two most important factors for mortality in burn patients are age and percent total body surface area burn (tbsa), which are unmodifiable findings. a predictable inflammatory response takes place after a burn injury leading to profound changes in patient homeostasis. as a result, hypoalbuminemia is one of the common finding in severe burn patients. 21% of hospitalized adult patients are hypoalbuminemic on admission. after admission, worsening of existing hypoalbuminemia and development of de novo one are frequently seen. moreover, hypoalbuminemia, a potentially modifiable variable, has been strongly associated with poor clinical outcomes in critically ill patients and in burn patients. dynamic organ dysfunction scores have been introduced in critically ill patients few years ago in order to describe the evolution of patients on a daily basis. the sequential organ failure assessment (sofa) score is now one of the most accepted score in critically ill patients and has been validated in general medico-surgical unit, as well as in trauma and cardiac surgery patients. it encompasses components assessing six organ functions. this score has also been shown to predict mortality in critically ill patients and in burn patients when used in a dynamic way.

Eligibility criteria:
inclusion criteria: 1. patients admitted to the bicu in the centre hospitalier de l'université de montréal within 24 hours following their thermal burn injury. 2. patients with second or third degree burns greater or equal than 20% of total body surface area. 3. patients aged 18 years or older. - exclusion criteria: 1. patients with serum albumin greater than 30 g/dl at the time of randomization. 2. patients with a do not resuscitate order. 3. patients needing total parenteral nutrition. 4. patients with the following chronic diseases that could affect baseline sofa calculation or serum albumin levels: end-stage kidney disease, nephrotic syndrome, hepatitis, exudative enteropaty, chronic thrombocytopenia or hematological malignancy. 5. patients with a known reaction to albumin. 6. pregnant or lactating women. 7. patients younger than 18 years old. -

Keywords: hypoalbuminemia burns albumin organ dysfunction outcome